TLR7 and neoplasm: In addition, intravenous injection of a self-assembling nanoparticle vaccine platform co-delivering tumor antigen and TLR7/8 agonist (SNP-7/8a) resulted in a higher frequency of CD8+PD-1+TCF-1+ cells and a significant tumor growth inhibition9.